Two thirds of patients with Crohn's disease require intestinal surgery at some time in their life. Intestinal strictures, that is narrowing of the bowel due to inflammation and scarring, are the most common reason for surgery. Despite the high frequency, associated disability, and cost there are no are no treatment strategies that aim to improve the outcome of this disease complication. The STRIDENT (stricture definition and treatment) studies aim to determine biochemical and imaging features associated with the development of strictures and in related STRIDENT studies develop strategies for treatment.
Patients with asymptomatic Crohn's disease strictures will be followed prospectively for 12 months using imaging (including MRI/intestinal ultrasound) and biochemical analyses (including CRP/calprotectin). Patient's with symptomatic or asymptomatic ulcerative colitis related strictures will be followed similarly. Risk factors for progression of strictures and development of symptoms will be identified.
Study Type
OBSERVATIONAL
Enrollment
9
St. Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
Development of symptoms
Number of patients who develop symptoms and require step up in therapy (drug, endoscopic or surgical therapy).
Time frame: 12 months
Imaging features associated with development of symptoms (MRI).
MaRIA
Time frame: 12 months
Imaging features associated with development of symptoms (Intestinal Ultrasound).
Limberg's score
Time frame: 12 months
Biochemical features associated with development of symptoms
CRP and calprotectin
Time frame: 12 months
Patient reported outcomes
SF36
Time frame: 12 months
Patient reported outcomes
IBDQ
Time frame: 12 months
Requirement for step up in drug therapy
Need for additional drug therapy due to development of symptoms
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.